Joseph Albanese, DO
Nephrology · Brick, NJNPI 1306850599
Payments from drug & device makers
Across 449 payments — averaging $92.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$30K
- Lilly USA, LLC$4K
- AstraZeneca$1K
- Novo Nordisk$773
- Amgen$637
- Otsuka America Pharmaceutical, Inc.$443
- plus $5K from 38 others
What the payments were for
- Speaking & faculty fees$29,07870%
- Travel & lodging$2,5226%
- Food & beverage$9,53523%
- Education$2601%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$32,420
- COVERA$254
- ELLIPSYS VASCULAR ACCESS SYSTEM$132
- NURTEC ODT$125
- XPHOZAH 30 MG$125
- XARELTO$122
- INVOKANA$121
- LOKELMA$120
- RYBELSUS$120
- Ozempic$118
- NEXLIZET$106
- NEXLETOL$106
How this compares
$41,394 in reported general payments places this provider in the 95th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 276 | $360,350 |
| FarxigaDapagliflozin Propanediol | 68 | $89,408 |
| OzempicSemaglutide | 45 | $66,477 |
| VelphoroSucroferric Oxyhydroxide | 15 | $34,537 |
| Cinacalcet Hcl | 52 | $32,394 |
| LokelmaSodium Zirconium Cyclosilicate | 31 | $26,528 |
| Sevelamer Carbonate | 154 | $23,863 |
| Lanthanum Carbonate | 27 | $19,647 |
| RenvelaSevelamer Carbonate | 14 | $18,955 |
| Potassium Citrate ErPotassium Citrate | 107 | $18,532 |
| SpsSodium Polystyrene Sulfon/Sorb | 29 | $14,014 |
| Febuxostat | 46 | $8,387 |
| Nifedipine ErNifedipine | 211 | $7,843 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 169 | $7,544 |
| JanuviaSitagliptin Phosphate | 13 | $7,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $29,993 | $360,350276 claims |
| AstraZenecaFarxiga, Lokelma | $1,029 | $115,93699 claims |
| Novo NordiskOzempic | $773 | $66,47745 claims |
| Fresenius USA Marketing, Inc.Velphoro | $165 | $34,53715 claims |
| MerckJanuvia | $16 | $7,47013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Brick
- Robert BrunoBrick$9K
- Winicjusz PaleckiBrick$8K
- John DepalmaBrick$7K
- Angelo MarkatosBrick$6K
- Danny HaddadJersey City$1.7M
- Anup PatelWest Orange$1M
- Joshua KaplanNewark$509K
- Lawrence ByrdLivingston$338K
- Devang LodhaviaVoorhees$321K
- Jeffrey FeldmanUnion$315K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.